The adverse events rates listed below are based on symptoms spontaneously reported in multidose controlled clinical trials in comparing NASAREL and NASALIDE (flunisolide (nasal spray)) for treatment of allergic rhinitis. In patients receiving NASAREL the most common adverse events were transient aftertaste (17%) and transient nasal burning and stinging (13%). These symptoms did not usually interfere with treatment.

Adverse Event Rates for NASAREL:

Incidence Greater than 1% (probably causally related)

Respiratory: Nasal burning/stinging (13%), epistaxis *, nasal dryness, pharyngitis, cough increased

Gastrointestinal: Nausea

Special Senses: Aftertaste (17%)

Incidence 1% or Less (probably causally related)

Respiratory: Hoarseness

Special Senses: Abnormal sense of smell

Incidence 1% or Less (causal relationship unknown) *

Respiratory: Sinusitis

Adverse Event Rates for NASALIDE (flunisolide (nasal spray)) :

Incidence Greater than 1% (probably causally related)

Respiratory: Nasal burning/stinging (44%), epistaxis *, nasal dryness *, pharyngitis *, cough increased

Gastrointestinal: Nausea

Special Senses: Aftertaste (8%)

Incidence 1% or Less (probably causally related)

Respiratory: Hoarseness, nasal ulcer

Incidence 1% or Less (causal relationship unknown) Â

Respiratory: Sinusitis
________________________________________
*Incidence of reported reaction between 3% and 9%. Those reactions occurring in less than 3% of the patients are unmarked.
 Reactions occurred under circumstances where the causal relationship has not been clearly established; they are presented as alerting information for physicians.
Cases of growth suppression have been reported for intranasal corticosteroids (including NASAREL) (see PRECAUTIONS, Pediatric Use section).

Read the Nasalide (flunisolide (nasal spray)) Side Effects Center for a complete guide to possible side effects »

No information provided.

Last reviewed on RxList: 12/8/2004
This monograph has been modified to include the generic and brand name in many instances.